| 3 | 1/1 | 返回列表 |
| 查看: 853 | 回復(fù): 2 | ||
小木蟲(chóng)劉樹(shù)青木蟲(chóng) (著名寫手)
夜未眠
|
[求助]
求大神翻譯 只有一段哦,謝謝
|
|
In the future, it is likely that ctDNA and CTCs will have complementary roles as cancer biomarkers although separate approaches may have distinct advantages in specificclinicalcontexts. ctDNA analysis is appealing due to the ease with which plasma can be collected and analyzed without the prior need to enrich and isolate a rare population of cells. For this reason, ctDNA analysis is likely to be the preferred option for genotyping and monitoring treatment response. The analysis of ctDNA can be applied as a high-throughput strategy for the assessment of clinical samples, but is limited to the analysis of point mutations, structural rearrangements, copy number aberrations and changes in DNA methylation. In contrast, the analysis of CTCs provides the unique opportunity to study the whole cell, allowing DNA, RNA and protein-based molecular profiling, and the opportunity for functional studies to guide personalized treatment selection. Although the analysis of both ctDNA and CTCs pose several technical challenges, ongoing improvements are expected over coming years, and both approaches hold great promise as biomarkers in various facets of cancer management. Technological advances might allow in the future, the use of a liquid biopsy (CTCs or ctDNA) for earlier cancer diagnosis or detection of disease relapse/progression. However, it is not known if earlier detection will lead to improved patient outcomes. This will become possible only if effective treatments are available to target early recurrences. Another open question is whether the liquid biopsy will complement analysis of primary tumor or metastases for tailoring treatment selection. Ongoing interventional clinical trials using CTC detection and characterization by CellSearch® will provide initial answers on the above question. Future research will be focused on optimizing and standardizing new technologies for both ctDNA and CTC analysis, demonstrating appropriate analytical and clinical validity as well as establishing the clinical utility of ctDNA and CTC testing through appropriately designed prospective clinical trials. |

金蟲(chóng) (正式寫手)
| 3 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 293求調(diào)劑 +3 | 濤濤Wjt 2026-03-22 | 5/250 |
|
|---|---|---|---|---|
|
[考研] 284求調(diào)劑 +5 | Zhao anqi 2026-03-22 | 5/250 |
|
|
[考研] 293求調(diào)劑 +12 | zjl的號(hào) 2026-03-16 | 17/850 |
|
|
[考研] 能源材料化學(xué)課題組招收碩士研究生8-10名 +5 | 脫穎而出 2026-03-16 | 17/850 |
|
|
[考研] 318求調(diào)劑 +4 | plum李子 2026-03-21 | 7/350 |
|
|
[考研] 303求調(diào)劑 +5 | 安憶靈 2026-03-22 | 6/300 |
|
|
[考研]
|
酥酥魚(yú).. 2026-03-21 | 3/150 |
|
|
[考研] 286求調(diào)劑 +10 | Faune 2026-03-21 | 10/500 |
|
|
[考研] 279分求調(diào)劑 一志愿211 +14 | chaojifeixia 2026-03-19 | 15/750 |
|
|
[考研] 085601調(diào)劑 358分 +3 | zzzzggh 2026-03-20 | 4/200 |
|
|
[考研] 301求調(diào)劑 +10 | yy要上岸呀 2026-03-17 | 10/500 |
|
|
[考研] 一志愿中國(guó)石油大學(xué)(華東) 本科齊魯工業(yè)大學(xué) +3 | 石能偉 2026-03-17 | 3/150 |
|
|
[考研]
|
.6lL 2026-03-18 | 8/400 |
|
|
[考研] 南京大學(xué)化學(xué)376求調(diào)劑 +3 | hisfailed 2026-03-19 | 6/300 |
|
|
[考研] 261求B區(qū)調(diào)劑,科研經(jīng)歷豐富 +3 | 牛奶很忙 2026-03-20 | 4/200 |
|
|
[考研] 086500 325 求調(diào)劑 +3 | 領(lǐng)帶小熊 2026-03-19 | 3/150 |
|
|
[考研] 材料與化工求調(diào)劑 +7 | 為學(xué)666 2026-03-16 | 7/350 |
|
|
[考研] 0703化學(xué)調(diào)劑 +3 | 妮妮ninicgb 2026-03-17 | 3/150 |
|
|
[考研] 一志愿蘇州大學(xué)材料工程(085601)專碩有科研經(jīng)歷三項(xiàng)國(guó)獎(jiǎng)兩個(gè)實(shí)用型專利一項(xiàng)省級(jí)立項(xiàng) +6 | 大火山小火山 2026-03-16 | 8/400 |
|
|
[考研] 070300化學(xué)學(xué)碩求調(diào)劑 +6 | 太想進(jìn)步了0608 2026-03-16 | 6/300 |
|